About
Andy is focused on advancing health and human life. He enjoys bringing bold and innovative teams together to improve healthcare outcomes and reduce cost. He is the founder and CEO of Koya Medical, a team dedicated to transforming venous and lymphatic disease. He is also Chairman and board director with Rivermark Medical, a first-line urological care and Aquea Health, an innovative glaucoma care. Previously, he led Oculeve, a first-in-class health venture backed by NEA, Kleiner Perkins, and Versant to treat ocular disorders with a revolutionary neuromodulation platform. The company was acquired by Allergan Plc. Prior to this, Andy invented sight-restoring intraocular implants that have given sight to more than 6 million humans across the globe. This technology was acquired by Santen Pharmaceuticals and licensed to Bausch & Lomb (marketed as envista IOL). He is trained as a scientist with a specialization in biomedical applications to solve diseases and extend healthy human life. A
Position in the VCSift Database
- • 15 investors hold the President/CEO role in VCSift. Andy Doraiswamy is one of them.
- • 214 investors are based in Oakland, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Stages
- series-a
- Location
- Oakland, US
Contact Information
Find more investors like Andy
Search Investors